HIPEC
Dr. Breazu
Synopsis
1 Methods
We used medians (with range) or frequencies (with %) to describe the data as appropriate. We further studied the differences between patients with Oxaliplatin and Cisplatin Chemotherapy using Mann-Whitney (MW) or T tests, Odds-Ratios (OR, with Wald 95% confidence intervals) followed by Fisher’s tests or Cramér V coefficients followed by chi-square tests as appropriate. P < 0.05 were considered statistically significant. We performed all analysis in R version 3.6.0 [R] for all remaining analyses and plots was used. [ All anonymized data, R code and the markdown file are available online on Github repository XXXXXX ].
2 Results
2.1 AKI (yes/no)
Table 1: selected paramenters by AKI.Factor | Detalis | yes | no | Total | Statistics |
Acure kidney injury | 4 (7.8%) | 47 (92.2%) | 51 | ||
Sex | F | 2 (50.0%) | 37 (78.7%) | 39 (76.5%) | OR=0.27 [0.03, 2.16], RR=0.64 [0.29, 1.38] (p=0.232) |
M | 2 (50.0%) | 10 (21.3%) | 12 (23.5%) | ||
Age (years) | μ ±DS | 64.50 ±7.51 | 54.83 ±9.84 | 55.59 ±9.97 | MW: p=0.068 |
M (min:max) | 66 (55:71) | 57 (24:69) | 57 (24:71) | ||
Weight (kg) | μ ±DS | 85.00 ±13.7 | 78.17 ±14.7 | 78.71 ±14.6 | T-test: p=0.376 |
M (min:max) | 83.5 (70:103) | 78 (47:115) | 78 (47:115) | ||
Peritoneal cancer index (PCI) | μ ±DS | 7.50 ±5.51 | 10.98 ±6.08 | 10.70 ±6.06 | MW: p=0.306 |
M (min:max) | 7 (2:14) | 10 (1:23) | 10 (1:23) | ||
Peridural | 3 (75.0%) | 42 (89.4%) | 45 (88.2%) | OR=0.36 [0.03, 4.12], RR=0.84 [0.57, 1.23] (p=0.404) | |
Blood units | 0 | 2 (50.0%) | 40 (85.1%) | 42 (82.4%) | V=0.31 (p=0.087) |
1 | 2 (50.0%) | 5 (10.6%) | 7 (13.7%) | ||
2 | 0 | 2 (4.3%) | 2 (3.9%) | ||
Plasma units | 0 | 3 (75.0%) | 40 (85.1%) | 43 (84.3%) | V=0.33 (p=0.140) |
1 | 1 (25.0%) | 1 (2.1%) | 2 (3.9%) | ||
2 | 0 | 4 (8.5%) | 4 (7.8%) | ||
3 | 0 | 0 | 0 | ||
4 | 0 | 2 (4.3%) | 2 (3.9%) | ||
Blood loss (mL) | μ ±DS | 375.00 ±419.3 | 271.28 ±305.9 | 279.41 ±312.1 | MW: p=0.488 |
M (min:max) | 200 (100:1000) | 200 (0:1500) | 200 (0:1500) | ||
Intraoperative crystalloids (mL) | μ ±DS | 3000.00 ±707.1 | 5817.02 ±2782.4 | 5596.08 ±2781.7 | MW: p=0.012 |
M (min:max) | 3250 (2000:3500) | 5500 (2000:16300) | 5500 (2000:16300) | ||
Intraoperative colloids (mL) | μ ±DS | 500.00 ±707.1 | 297.87 ±496.3 | 313.73 ±509.5 | MW: p=0.546 |
M (min:max) | 250 (0:1500) | 0 (0:2500) | 0 (0:2500) | ||
ASA | 2 | 2 (50.0%) | 21 (44.7%) | 23 (45.1%) | OR=1.24 [0.16, 9.55], RR=1.12 [0.49, 2.54] (p=1.000) |
3 | 2 (50.0%) | 26 (55.3%) | 28 (54.9%) | ||
Surgery duration (hours) | μ ±DS | 5.17 ±0.782 | 7.15 ±2.38 | 7.00 ±2.35 | MW: p=0.053 |
M (min:max) | 5.08 (4.5:6) | 7 (3:15) | 6.5 (3:15) | ||
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); | |||||
Table 2: All paramenters by AKI.Factor | Detalis | yes | no | Total | Statistics |
Acure kidney injury | 4 (7.8%) | 47 (92.2%) | 51 | ||
Location | ovary | 2 (50.0%) | 27 (57.4%) | 29 (56.9%) | V=0.17 (p=0.677) |
colon | 2 (50.0%) | 12 (25.5%) | 14 (27.5%) | ||
appendix | 0 | 5 (10.6%) | 5 (9.8%) | ||
others | 0 | 3 (6.4%) | 3 (5.9%) | ||
Sex | F | 2 (50.0%) | 37 (78.7%) | 39 (76.5%) | OR=0.27 [0.03, 2.16], RR=0.64 [0.29, 1.38] (p=0.232) |
M | 2 (50.0%) | 10 (21.3%) | 12 (23.5%) | ||
Age (years) | μ ±DS | 64.50 ±7.51 | 54.83 ±9.84 | 55.59 ±9.97 | MW: p=0.068 |
M (min:max) | 66 (55:71) | 57 (24:69) | 57 (24:71) | ||
Height (m) | μ ±DS | 1.70 ±0.0419 | 1.67 ±0.0769 | 1.67 ±0.0751 | T-test: p=0.358 |
M (min:max) | 1.69 (1.66:1.76) | 1.65 (1.54:1.9) | 1.66 (1.54:1.9) | ||
Weight (kg) | μ ±DS | 85.00 ±13.7 | 78.17 ±14.7 | 78.71 ±14.6 | T-test: p=0.376 |
M (min:max) | 83.5 (70:103) | 78 (47:115) | 78 (47:115) | ||
BMI (kg/m²) | μ ±DS | 29.23 ±3.59 | 28.06 ±4.3 | 28.15 ±4.23 | T-test: p=0.600 |
M (min:max) | 29.58 (24.51:33.25) | 28.37 (19.07:37.47) | 29.32 (19.07:37.47) | ||
Peritoneal cancer index (PCI) | μ ±DS | 7.50 ±5.51 | 10.98 ±6.08 | 10.70 ±6.06 | MW: p=0.306 |
M (min:max) | 7 (2:14) | 10 (1:23) | 10 (1:23) | ||
Plasma units | 0 | 3 (75.0%) | 40 (85.1%) | 43 (84.3%) | V=0.33 (p=0.140) |
1 | 1 (25.0%) | 1 (2.1%) | 2 (3.9%) | ||
2 | 0 | 4 (8.5%) | 4 (7.8%) | ||
3 | 0 | 0 | 0 | ||
4 | 0 | 2 (4.3%) | 2 (3.9%) | ||
ASA | 2 | 2 (50.0%) | 21 (44.7%) | 23 (45.1%) | OR=1.24 [0.16, 9.55], RR=1.12 [0.49, 2.54] (p=1.000) |
3 | 2 (50.0%) | 26 (55.3%) | 28 (54.9%) | ||
Chemotherapy | Oxaliplatin | 2 (50.0%) | 17 (36.2%) | 19 (37.3%) | OR=1.76 [0.23, 13.68], RR=1.38 [0.59, 3.22] (p=0.623) |
Cisplatin | 2 (50.0%) | 30 (63.8%) | 32 (62.7%) | ||
Chemotherapy duration (minutes) | 30 | 2 (50.0%) | 19 (41.3%) | 21 (42.0%) | V=0.17 (p=0.487) |
60 | 0 | 12 (26.1%) | 12 (24.0%) | ||
90 | 2 (50.0%) | 15 (32.6%) | 17 (34.0%) | ||
HIPEC crystalloids (mL) | μ ±DS | 825.00 ±236.3 | 1372.34 ±648.6 | 1329.41 ±642.3 | MW: p=0.056 |
M (min:max) | 900 (500:1000) | 1000 (500:3500) | 1000 (500:3500) | ||
HIPEC diuresis (mL) | μ ±DS | 950.00 ±420.3 | 1079.79 ±496.1 | 1069.61 ±488.2 | MW: p=0.682 |
M (min:max) | 900 (500:1500) | 1000 (500:2500) | 1000 (500:2500) | ||
Total hospitalization (days) | μ ±DS | 11.25 ±2.22 | 16.79 ±8.14 | 16.35 ±7.97 | MW: p=0.065 |
M (min:max) | 12 (8:13) | 14 (3:42) | 14 (3:42) | ||
ITU hospitalization (days) | μ ±DS | 3.25 ±0.957 | 5.64 ±4.85 | 5.45 ±4.7 | MW: p=0.100 |
M (min:max) | 3.5 (2:4) | 4 (2:30) | 4 (2:30) | ||
Surgery duration (hours) | μ ±DS | 5.17 ±0.782 | 7.15 ±2.38 | 7.00 ±2.35 | MW: p=0.053 |
M (min:max) | 5.08 (4.5:6) | 7 (3:15) | 6.5 (3:15) | ||
Blood loss (mL) | μ ±DS | 375.00 ±419.3 | 271.28 ±305.9 | 279.41 ±312.1 | MW: p=0.488 |
M (min:max) | 200 (100:1000) | 200 (0:1500) | 200 (0:1500) | ||
Post-surgical complications | 0 | 21 (44.7%) | 21 (41.2%) | OR=0.14 [0.01, 2.69], RR=0.00 [0.00, 0.00] (p=0.134) | |
Reinterventions | 0 | 3 (6.4%) | 3 (5.9%) | OR=1.41 [0.06, 31.92], RR=0.00 [0.00, 0.00] (p=1.000) | |
Intraoperative crystalloids (mL) | μ ±DS | 3000.00 ±707.1 | 5817.02 ±2782.4 | 5596.08 ±2781.7 | MW: p=0.012 |
M (min:max) | 3250 (2000:3500) | 5500 (2000:16300) | 5500 (2000:16300) | ||
Intraoperative colloids (mL) | μ ±DS | 500.00 ±707.1 | 297.87 ±496.3 | 313.73 ±509.5 | MW: p=0.546 |
M (min:max) | 250 (0:1500) | 0 (0:2500) | 0 (0:2500) | ||
Blood units | 0 | 2 (50.0%) | 40 (85.1%) | 42 (82.4%) | V=0.31 (p=0.087) |
1 | 2 (50.0%) | 5 (10.6%) | 7 (13.7%) | ||
2 | 0 | 2 (4.3%) | 2 (3.9%) | ||
Peridural | 3 (75.0%) | 42 (89.4%) | 45 (88.2%) | OR=0.36 [0.03, 4.12], RR=0.84 [0.57, 1.23] (p=0.404) | |
Tumor reccurence (months) | 4 | 0 | 1 (20.0%) | 1 (20.0%) | V=NaN (p=1.000) |
5 | 0 | 1 (20.0%) | 1 (20.0%) | ||
9 | 0 | 2 (40.0%) | 2 (40.0%) | ||
13 | 0 | 1 (20.0%) | 1 (20.0%) | ||
Tumor reccurence | 0 | 8 (17.0%) | 8 (15.7%) | OR=0.52 [0.03, 10.52], RR=0.00 [0.00, 0.00] (p=1.000) | |
Diuresis (mL) | μ ±DS | 2525.00 ±340.3 | 2878.72 ±1231.1 | 2850.98 ±1187.7 | MW: p=0.779 |
M (min:max) | 2450 (2200:3000) | 2500 (1000:5800) | 2500 (1000:5800) | ||
Noradrenaline | 2 (50.0%) | 37 (78.7%) | 39 (76.5%) | OR=0.27 [0.03, 2.16], RR=0.64 [0.29, 1.38] (p=0.232) | |
Furosemide | 4 (100%) | 44 (93.6%) | 48 (94.1%) | OR=0.71 [0.03, 15.99], RR=1.07 (p=1.000) | |
Mannitol | 4 (100%) | 38 (80.9%) | 42 (82.4%) | OR=2.22 [0.11, 44.91], RR=1.24 (p=1.000) | |
Creatinine day 0 PO (mg/dL) | μ ±DS | 1.06 ±0.369 | 0.783 ±0.296 | 0.805 ±0.307 | MW: p=0.035 |
M (min:max) | 0.92 (0.8:1.6) | 0.7 (0.4:2.25) | 0.71 (0.4:2.25) | ||
Creatinine day 1 PO (mg/dL) | μ ±DS | 1.33 ±0.487 | 0.825 ±0.285 | 0.864 ±0.328 | MW: p=0.018 |
M (min:max) | 1.27 (0.8:1.98) | 0.8 (0.5:1.98) | 0.8 (0.5:1.98) | ||
Creatinine day 3 PO (mg/dL) | μ ±DS | 1.09 ±0.515 | 0.729 ±0.315 | 0.758 ±0.342 | MW: p=0.034 |
M (min:max) | 0.89 (0.74:1.85) | 0.68 (0.3:1.98) | 0.69 (0.3:1.98) | ||
Creatinine day 7 PO (mg/dL) | μ ±DS | 0.998 ±0.343 | 0.672 ±0.275 | 0.698 ±0.29 | MW: p=0.012 |
M (min:max) | 0.88 (0.74:1.5) | 0.64 (0.3:2.11) | 0.65 (0.3:2.11) | ||
Creatinine at discharge (mg/dL) | μ ±DS | 0.873 ±0.26 | 0.692 ±0.182 | 0.706 ±0.192 | MW: p=0.083 |
M (min:max) | 0.81 (0.64:1.23) | 0.7 (0.4:1.49) | 0.7 (0.4:1.49) | ||
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); | |||||
2.2 Surgery duration vs AKI
According to the log-rank test, which may be more accurate for the comparrison of surgery duration by AKI, AKI patients had significantly shorter median surgery (p = 0.008).
2.3 Chemotherapy vs. Main
Table 3: Main parameters by chemotherapy.Factor | Detalis | Oxaliplatin | Cisplatin | Total | Statistics |
Chemotherapy | 19 (37.3%) | 32 (62.7%) | 51 | ||
Location | ovary | 0 | 29 (90.6%) | 29 (56.9%) | V=1.00 (p<0.001) |
colon | 14 (73.7%) | 0 | 14 (27.5%) | ||
appendix | 5 (26.3%) | 0 | 5 (9.8%) | ||
others | 0 | 3 (9.4%) | 3 (5.9%) | ||
Sex | F | 7 (36.8%) | 32 (100%) | 39 (76.5%) | OR=0.01 [0.00, 0.17], RR=0.37 [0.21, 0.64] (p<0.001) |
M | 12 (63.2%) | 0 | 12 (23.5%) | ||
Age (years) | μ ±DS | 56.58 ±9.73 | 55.00 ±10.2 | 55.59 ±9.97 | MW: p=0.598 |
M (min:max) | 58 (35:71) | 57 (24:69) | 57 (24:71) | ||
Height (m) | μ ±DS | 1.69 ±0.0953 | 1.66 ±0.0581 | 1.67 ±0.0751 | Welch: p=0.168 |
M (min:max) | 1.7 (1.55:1.9) | 1.65 (1.54:1.76) | 1.66 (1.54:1.9) | ||
Weight (kg) | μ ±DS | 82.42 ±15.8 | 76.50 ±13.7 | 78.71 ±14.6 | T-test: p=0.165 |
M (min:max) | 81 (47:115) | 76 (54:103) | 78 (47:115) | ||
BMI (kg/m²) | μ ±DS | 28.67 ±3.96 | 27.84 ±4.4 | 28.15 ±4.23 | T-test: p=0.500 |
M (min:max) | 29.39 (19.07:34.34) | 28.37 (19.13:37.47) | 29.32 (19.07:37.47) | ||
Peritoneal cancer index (PCI) | μ ±DS | 10.95 ±5.74 | 10.55 ±6.34 | 10.70 ±6.06 | MW: p=0.645 |
M (min:max) | 11 (2:22) | 10 (1:23) | 10 (1:23) | ||
Plasma units | 0 | 15 (78.9%) | 28 (87.5%) | 43 (84.3%) | V=0.28 (p=0.276) |
1 | 0 | 2 (6.2%) | 2 (3.9%) | ||
2 | 3 (15.8%) | 1 (3.1%) | 4 (7.8%) | ||
3 | 0 | 0 | 0 | ||
4 | 1 (5.3%) | 1 (3.1%) | 2 (3.9%) | ||
ASA | 2 | 12 (63.2%) | 11 (34.4%) | 23 (45.1%) | OR=3.27 [1.00, 10.69], RR=1.84 [1.04, 3.23] (p=0.080) |
3 | 7 (36.8%) | 21 (65.6%) | 28 (54.9%) | ||
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); | |||||
Figure 1: 
Figure 2: Main parameters distributions by Chemotherapy.
2.4 Chemotherapy vs. Chemotherapy
Table 4: Chemotherapy parameters by chemotherapy.Factor | Detalis | Oxaliplatin | Cisplatin | Total | Statistics |
Chemotherapy | 19 (37.3%) | 32 (62.7%) | 51 | ||
Chemotherapy duration (minutes) | 30 | 19 (100%) | 2 (6.5%) | 21 (42.0%) | V=0.92 (p<0.001) |
60 | 0 | 12 (38.7%) | 12 (24.0%) | ||
90 | 0 | 17 (54.8%) | 17 (34.0%) | ||
HIPEC crystalloids (mL) | μ ±DS | 1257.89 ±558.1 | 1371.88 ±692.5 | 1329.41 ±642.3 | MW: p=0.664 |
M (min:max) | 1000 (500:2500) | 1000 (500:3500) | 1000 (500:3500) | ||
HIPEC diuresis (mL) | μ ±DS | 910.53 ±313.8 | 1164.06 ±550.0 | 1069.61 ±488.2 | MW: p=0.129 |
M (min:max) | 800 (500:1500) | 1000 (500:2500) | 1000 (500:2500) | ||
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); | |||||
Figure 3: HIPEC intake of crytalloids and diuresis.
Figure 4: HIPEC distributions by Chemotherapy.
2.5 Chemotherapy vs. Hospitalization
The tables below show hospitalization durations (total and ICU) in both groups. The MW test (chosen automatically) is not the optimal preceudure. A better option is the log-rank test, which yields similar conclusions but with siglty different p-values: p = 0.188 (total stay) and p = 0.097 (ICU stay). Overall, both groups had statistically similar hospitalization durations.
Table 5: Hospitalization parameters by chemotherapy.Factor | Detalis | Total | Oxaliplatin | Cisplatin | Statistics |
Chemotherapy | 51 | 19 (37.3%) | 32 (62.7%) | ||
Total hospitalization (days) | μ ±DS | 16.35 ±7.97 | 18.32 ±9.39 | 15.19 ±6.89 | MW: p=0.204 |
M (min:max) | 14 (3:42) | 15 (3:42) | 13.5 (8:42) | ||
ITU hospitalization (days) | μ ±DS | 5.45 ±4.7 | 6.63 ±6.11 | 4.75 ±3.56 | MW: p=0.056 |
M (min:max) | 4 (2:30) | 5 (2:30) | 4 (2:22) | ||
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); | |||||
Figure 5: Kaplan Meier plots of the hospitalization (total and ICU only) durations by chemotherapy. Tufte-box-plots and log-rank test p-values were added.
Figure 6: Hospitalization durations distributions by Chemotherapy.
2.6 Chemotherapy vs. Surgery
Similarly, the log-rank test is a better alternative to the MW test for the surgery duration, with a p-value of 0.609, meaning that surgery duration was statistically similar in both groups.
Table 6: Surgery parameters by chemotherapy.Factor | Detalis | Total | Oxaliplatin | Cisplatin | Statistics |
Chemotherapy | 51 | 19 (37.3%) | 32 (62.7%) | ||
Surgery duration (hours) | μ ±DS | 7.00 ±2.35 | 7.20 ±2.45 | 6.87 ±2.32 | MW: p=0.564 |
M (min:max) | 6.5 (3:15) | 7 (3:12) | 6.25 (4:15) | ||
Blood loss (mL) | μ ±DS | 279.41 ±312.1 | 252.63 ±359.2 | 295.31 ±285.5 | MW: p=0.216 |
M (min:max) | 200 (0:1500) | 100 (0:1500) | 200 (0:1000) | ||
Post-surgical complications | 21 (41.2%) | 12 (63.2%) | 9 (28.1%) | OR=4.38 [1.31, 14.68], RR=2.25 [1.20, 4.19] (p=0.020) | |
Reinterventions | 3 (5.9%) | 2 (10.5%) | 1 (3.1%) | OR=3.65 [0.31, 43.21], RR=3.37 [0.48, 23.51] (p=0.547) | |
Intraoperative crystalloids (mL) | μ ±DS | 5596.08 ±2781.7 | 6410.53 ±3652.5 | 5112.50 ±2021.3 | MW: p=0.323 |
M (min:max) | 5500 (2000:16300) | 5500 (2500:16300) | 5000 (2000:12000) | ||
Intraoperative colloids (mL) | μ ±DS | 313.73 ±509.5 | 447.37 ±524.3 | 234.38 ±491.6 | MW: p=0.081 |
M (min:max) | 0 (0:2500) | 500 (0:1500) | 0 (0:2500) | ||
Blood units | 0 | 42 (82.4%) | 15 (78.9%) | 27 (84.4%) | V=0.07 (p=0.871) |
1 | 7 (13.7%) | 3 (15.8%) | 4 (12.5%) | ||
2 | 2 (3.9%) | 1 (5.3%) | 1 (3.1%) | ||
Peridural | 45 (88.2%) | 18 (94.7%) | 27 (84.4%) | OR=3.33 [0.36, 30.95], RR=1.12 [0.96, 1.32] (p=0.392) | |
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); | |||||
Figure 7: Surgery parameters by chemotherapy.
Figure 8: Surgery parameters distribution by Chemotherapy.
2.7 Chemotherapy vs. Reccurence
Table 7: Reccurence parameters by chemotherapy.Factor | Detalis | Oxaliplatin | Cisplatin | Total | Statistics |
Chemotherapy | 19 (37.3%) | 32 (62.7%) | 51 | ||
Tumor reccurence | 5 (26.3%) | 3 (9.4%) | 8 (15.7%) | OR=3.45 [0.72, 16.55], RR=2.81 [0.83, 9.45] (p=0.131) | |
Tumor reccurence (months) | 4 | 1 (25.0%) | 0 | 1 (20.0%) | V=1.00 (p=0.172) |
5 | 0 | 1 (100%) | 1 (20.0%) | ||
9 | 2 (50.0%) | 0 | 2 (40.0%) | ||
13 | 1 (25.0%) | 0 | 1 (20.0%) | ||
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); | |||||
Figure 9: Reccurence parameters by chemotherapy
2.8 Chemotherapy vs. Kidney
Table 8: Kidney parameters by chemotherapy.Factor | Detalis | Total | Oxaliplatin | Cisplatin | Statistics |
Chemotherapy | 51 | 19 (37.3%) | 32 (62.7%) | ||
Diuresis (mL) | μ ±DS | 2850.98 ±1187.7 | 3100.00 ±1358.5 | 2703.12 ±1069.1 | MW: p=0.279 |
M (min:max) | 2500 (1000:5800) | 3000 (1200:5800) | 2400 (1000:5000) | ||
Noradrenaline | 39 (76.5%) | 16 (84.2%) | 23 (71.9%) | OR=2.09 [0.49, 8.93], RR=1.17 [0.89, 1.54] (p=0.497) | |
Furosemide | 48 (94.1%) | 17 (89.5%) | 31 (96.9%) | OR=0.27 [0.02, 3.25], RR=0.92 [0.80, 1.06] (p=0.547) | |
Mannitol | 42 (82.4%) | 13 (68.4%) | 29 (90.6%) | OR=0.22 [0.05, 1.04], RR=0.75 [0.56, 1.02] (p=0.062) | |
Acure kidney injury | 4 (7.8%) | 2 (10.5%) | 2 (6.2%) | OR=1.76 [0.23, 13.68], RR=1.68 [0.32, 8.85] (p=0.623) | |
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); | |||||
Figure 10: Kidney parameters by chemotherapy.
Figure 11: Iuresis distribution by Chemotherapy.
2.9 Chemotherapy vs. Creatinine
Table 9: Creatinine parameters by chemotherapy.Factor | Detalis | Total | Oxaliplatin | Cisplatin | Statistics |
Chemotherapy | 51 | 19 (37.3%) | 32 (62.7%) | ||
Creatinine day 0 PO (mg/dL) | μ ±DS | 0.805 ±0.307 | 0.91 ±0.407 | 0.743 ±0.214 | MW: p=0.057 |
M (min:max) | 0.71 (0.4:2.25) | 0.73 (0.56:2.25) | 0.7 (0.4:1.52) | ||
Creatinine day 1 PO (mg/dL) | μ ±DS | 0.864 ±0.328 | 0.92 ±0.419 | 0.831 ±0.263 | MW: p=0.704 |
M (min:max) | 0.8 (0.5:1.98) | 0.8 (0.5:1.98) | 0.8 (0.52:1.88) | ||
Creatinine day 3 PO (mg/dL) | μ ±DS | 0.758 ±0.342 | 0.833 ±0.442 | 0.713 ±0.265 | MW: p=0.807 |
M (min:max) | 0.69 (0.3:1.98) | 0.65 (0.44:1.98) | 0.7 (0.3:1.84) | ||
Creatinine day 7 PO (mg/dL) | μ ±DS | 0.698 ±0.29 | 0.746 ±0.414 | 0.669 ±0.185 | MW: p=0.953 |
M (min:max) | 0.65 (0.3:2.11) | 0.64 (0.3:2.11) | 0.66 (0.4:1.18) | ||
Creatinine at discharge (mg/dL) | μ ±DS | 0.706 ±0.192 | 0.768 ±0.24 | 0.669 ±0.15 | MW: p=0.191 |
M (min:max) | 0.7 (0.4:1.49) | 0.7 (0.58:1.49) | 0.7 (0.4:1.08) | ||
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); | |||||
Figure 12: Creatinine evolution by chemotherapy.
Table 10: Creatinine evolution by chemotherapy. ANOVA table.Effect | DF n/d | F | p | p[GG] | p[HF] | ges |
Chemotherapy | 1/49 | 1.96 | 0.168 | NA | NA | 0.033 |
Measurement | 4/196 | 15.73 | <0.001 | <0.001 | <0.001 | 0.045 |
Chemotherapy:Measurement | 4/196 | 0.95 | 0.437 | 0.418 | 0.423 | 0.003 |
ges = Generalized eta-squared | ||||||
Sphericity adjustemtes: GG = Greenhouse-Guisser, HF = Huynh-Fieldt. | ||||||
Mauchly's Test for Sphericity: W=0.537, p<0.001 | ||||||
Table 11: Creatinine evolution: Pairwise comparisons using paired T-tests.vs. | day 0 PO | day 1 PO | day 3 PO | day 7 PO |
day 1 PO | 0.042 | |||
day 3 PO | 0.172 | 0.000 | ||
day 7 PO | 0.000 | 0.000 | 0.172 | |
at discharge | 0.001 | 0.000 | 0.211 | 0.685 |
P value adjustment method: Holm | ||||
A repeated measuremets ANOVA model pruduced the results above. While time has a signifficant effect on creatinine, chemotherapy does not (in isolation and in interaction across time). The significant pairs of measurements are marked on the box-plot and the table above. Acording to the Mauchly’s Test for Sphericity (W=0.546, p<0.001), corrections are necessary. However, after applying either Huynh-Feldt and Greenhouse-Geisser, the conclusions did not change.
Figure 13: Creatinine distribution by Chemotherapy.
2.10 Chemotherapy vs. Other
Figure 14: Other parameters by chemotherapy.
3 References
R. R Core Team (2018). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/